Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors

REFERENCES

• Aaronson S.A. Growth Factors and Cancer. Science 1991; 254: 1146–1153
   PubMed Web of Science ®Google Scholar
• Cantley L.C., Auger K.R., Carpenter C., Duckworth B., Graziani A., Kapeller R., Soltoff S. Oncogenes and Signal Transduction. Cell 1991; 64: 281–302
   PubMed Web of Science ®Google Scholar
• Al-Obeidi F.A., Wu J.J., Lam K.S. Protein Tyrosine Kinases: Structure, Substrate, Specificity and Drug Discovery. Biopolymers 1998; 47: 197–223
   PubMed Web of Science ®Google Scholar
• Gullick W.J. Prevalence of Aberrant Expression of the Epidermal Growth Factor Receptor in Human Cancers. Br. Med. Bull. 1991; 47: 87–98
   PubMed Web of Science ®Google Scholar
• Hanks S.K., Quinn A.M., Hunter T. The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains. Science 1988; 241: 42–51
   PubMed Web of Science ®Google Scholar
• Ullrich A., Schlessinger J. Signal Transduction by Receptors with Tyrosine Kinase Activity. Cell 1990; 61: 203–212
   PubMed Web of Science ®Google Scholar
• Koch C.A., Anderson D., Moran M.F., Ellis C., Pawson T. SH2 and SH3 Domains: Elements that Control Interactions of Cytoplasmic Signaling Proteins. Science 1991; 252: 668–674
   PubMed Web of Science ®Google Scholar
• Anderson D., Koch C., Grey L., Ellis C., Moran M.F., Pawson T. Binding of SH2 Domains of Phospholipase Cγ1, GAP and Src to Activated Growth Factor Receptors. Science 1990; 250: 979–982
   PubMed Web of Science ®Google Scholar
• Bolen J.B. Nonreceptor Tyrosine Protein Kinases. Oncogene 1993; 8: 2025–2031
   PubMed Web of Science ®Google Scholar
• Taniguchi T. Cytokine Signaling Through Nonreceptor Protein Tyrosine Kinases. Science 1995; 268: 251–255
   PubMed Web of Science ®Google Scholar
• Hunter T. Protein Kinases and Phosphatases: the Yin and Yang of Protein Phosphorylation and Signaling. Cell 1995; 80: 225–236
   PubMed Web of Science ®Google Scholar
• Weiner D.B., Liu J., Cohen J.A., Williams W.V., Greene M.I. A Point Mutation in the neu Oncogene Mimics Ligand Induction of Receptor Aggregation. Nature 1989; 339: 230–231
   PubMed Web of Science ®Google Scholar
• Ullrich A., Coussens L., Hayflick J.S., Dull T.J., Gray A., Tam A.W., Yarden L.J., Libermann T.A., Schlessinger J. Human Epidermal Growth Factor Receptor cDNA Sequence and Aberrant Expression of the Amplified Gene in A431 Epidermoid Carcinoma Cells. Nature 1984; 309: 418–425
   PubMed Web of Science ®Google Scholar
• Besmer P., Lader E., George P.C., Bergold P.J., Qiu F.H., Zuckermann E.E., Hardy W.D. A New Acute Transforming Feline Retrovirus With fms Homology Specifies a C-Terminally Truncated Version of The c-fams Protein That Is Different from SM-Feline Sarcoma Virus v-fms Protein. J. Virol. 1986; 60: 194–203
   PubMed Web of Science ®Google Scholar
• Shu H.K., Pelley R.J., Kung H.J. Tissue Specific Transformation by Epidermal Growth Factor Receptor: a Single Point Mutation Within the ATP-Binding Pocket of the erbB Product Increases Its Intrinsic Kinase Activity and Activates Its Sarcomagenic Potential. Proc. Natl Acad. Sci. USA 1990; 87: 9103–9107
   PubMed Web of Science ®Google Scholar
• McDonough S.K., Larsen S., Brodey R.S., Stock N.D., Hardy W.D., Jr. A Transmissible Feline Fibrosarcoma of Viral Origin. Cancer Res. 1971; 31: 953–956
   PubMed Web of Science ®Google Scholar
• Ross J.S., Fletcher J.A. The her2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor and Target for Therapy. Stem Cells 1998; 16: 413–428
   PubMed Web of Science ®Google Scholar
• Baselga J., Mendelsohn J. The Epidermal Growth Factor Receptor as a Target for Therapy in Breast Carcinoma. Breast Cancer Res. Treat. 1994; 29: 127–138
   PubMed Web of Science ®Google Scholar
• Mausi H., Kawamoto T., Sato J.D., Wolf B., Sato G., Mendelsohn J. Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-epidermal Growth Factor Receptor Monoclonal Antibodies. Cancer Res. 1984; 44: 1002–1007
   PubMed Web of Science ®Google Scholar
• Bacus S.S., Yarden Y., Oren M., Chin D.M., Lyass L., Zelnick C.R., Kazarov A., Toyofuku W., Gray-Bablin J., Beerli R.R., Hynes N.E., Nikiforov M., Haffner R., Gudkov A., Keyomarsi K. Neu Differentiation Factor (Heregulin) Activates a p53-Dependent Pathway in Cancer Cells. Oncogene 1996; 12: 2535–2547
   PubMed Web of Science ®Google Scholar
• Goldenberg M.M. Trastuzumab, a Recombinant DNA-Derived Humanized Monoclonal Antibody, a Novel Agent for the Treatment of Metastatic Breast Cancer. Clin. Ther. 1999; 21: 309–318
   PubMed Web of Science ®Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu Overexpressing Metastatic Breast Cancer. J. Clin. Oncol. 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Norton L., Slamon D., Leyland-Jones B., Wolter J., Fleming T., Eirmann W., Baselga J., Mendelsohn J., Bajamonde A., Ash M., Shak S. Overall Survival Advantage to Simultaneous Chemotherapy Plus Humanized Anti-HER2 Monoclonal Antibody Herceptin in her2-Overexpressing Metastatic Breast Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 127a
   Google Scholar
• Ewer M.S., Gibbs H.R., Swafford J., Benjamin R.S. Cardiotoxicity in Patients Receiving Trastuzumab (Herceptin): Primary Toxicity, Synergistic or Sequential Stress or Surveillance Artifact. Semin. Oncol. 1999; 26((suppl. 12))96–101
   PubMed Web of Science ®Google Scholar
• Haeder M., Rotsch M., Bepler G., Hennig C., Havemann K., Heimann B., Moelling K. Epidermal Growth Factor Receptor Expression in Human Lung Cancer Cell Lines. Cancer Res. 1988; 48: 1132–1136
   PubMed Web of Science ®Google Scholar
• Shin D.M., Ro J.Y., Hong W.K., Hittelman W.N. Dysregulation of Epidermal Growth Factor Receptor Expression in Premalignant Lesions During Head and Neck Tumorigenesis. Cancer Res. 1994; 54: 3153–3159
   PubMed Web of Science ®Google Scholar
• Diedrich U., Lucius J., Baron E., Behnke J., Pabst B., Zoll B. Distribution of Epidermal Growth Factor Receptor Gene Amplification in Brain Tumors and Correlation to Prognosis. J. Neurol. 1995; 242: 683–688
   PubMed Web of Science ®Google Scholar
• Harris A.L., Nicholson S., Sainsbury R., Wright C., Farndon J. Epidermal Growth Factor Receptor and Other Oncogenes as Prognostic Markers. J. Natl Cancer Inst. Monogr. 1992; 11: 181–187
   PubMedGoogle Scholar
• Huang S., Harari P.M. Effects of Antiepidermal Growth Factor Receptor Monoclonal Antibody 225 (m225) on Proliferation, Apoptosis and Radiosensitivity in Human Squamous Cell Carcinomas of the Head and Neck. Proc. Am. Soc. Cancer Res. 1998; 39: 64
   Google Scholar
• Ezekiel M.P., Bonner J.A., Robert F., Meredith R.F., Spencer S.A., LoBuglio A.F., Waksal H.W. Phase I Trial of Chimerized Anti-Epidermal Growth Factor Receptor (Anti-EGFR) Antibody in Combination with Either Once Daily or Twice Daily Irradiation for Locally Advanced Head and Neck Malignancies. Proc. Am. Soc. Clin. Oncol. 1999; 18: 388a
   Google Scholar
• Mendelsohn J., Shin D.M., Donato N., Khuri F., Radinsky R., Glisson B.S., Shin H.J., Metz E., Pfister D., Perez-Soler R., Lawhorn K., Matsumoto T., Gunnett K., Falcey J., Waksal H., Hong W.K. A Phase I Study of Chimerized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 in Combination with Cisplatin in Patients with Recurrent Head and Neck Squamous Cell Carcinoma. Proc. Am. Soc. Clin. Oncol. 1999; 18: 389a
   Google Scholar
• Bos M., Mendelsohn J., Kim Y.M., Albanell J., Fry D.W., Baselga J. PD153035, a Tyrosine Kinase Inhibitor, Prevents Epidermal Growth Factor Receptor Activation and Inhibits Growth of Cancer Cells in a Receptor Number Dependent Manner. Clin. Cancer Res. 1997; 3: 2099–2106
   PubMed Web of Science ®Google Scholar
• Boutin J.A. Tyrosine Protein Kinase Inhibitor and Cancer. Int. J. Biochem. 1994; 26: 1203–1226
   PubMedGoogle Scholar
• Levitzki A., Gazit A. Tyrosine Kinase Inhibition: an Approach to Drug Development. Science 1995; 267: 1782–1788
   PubMed Web of Science ®Google Scholar
• Fry D.W. Recent Advances in Tyrosine Kinase Inhibitors. Annu. Rep. Med. Chem. 1996; 31: 151–160
   Web of Science ®Google Scholar
• Klohs W.D., Fry D.W., Kraker A.J. Inhibitors of Tyrosine Kinase. Curr. Opin. Oncol. 1997; 9: 562–568
   PubMedGoogle Scholar
• Lawrence D.S., Niu J. Protein Kinase Inhibitors: the Tyrosine Specific Protein Kinases. Pharmacol. Ther. 1998; 77: 81–114
   PubMed Web of Science ®Google Scholar
• McMahon G., Sun L., Liang C. Protein Kinase Inhibitors Structural Determinants for Target Specificity. Curr. Opin. Drug Discov. Dev. 1998; 1: 131–146
   PubMedGoogle Scholar
• Rewcastle G.W., Denny W.A., Bridges A.J., Zhou H., Cody D.R., McMichael A., Fry D.W. Tyrosine Kinase Inhibitors 5. Synthesis and Structure–Activity Relationships for 4-[(Phenylmethyl)Amino]- and 4-(Phenylamino) Quinazolones as Potent Adenosine 5′Triphosphate Binding Site Inhibitors of Epidermal Growth Factor Receptors. J. Med. Chem. 1995; 38: 3482–3487
   PubMed Web of Science ®Google Scholar
• Rewcastle G.W., Palmer B.D., Bridges A.J., Showalter H.D., Sun L., Nelson J., McMichael A., Kraker A.J., Fry D.W., Denny W.A. Tyrosine Kinase Inhibitors 9. Synthesis and Evaluation of Fused Tricyclic Quinazolone Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptors. J. Med. Chem. 1996; 39: 918–928
   PubMed Web of Science ®Google Scholar
• Rewcastle G.W., Bridges A.J., Fry D.W., Rubin J.R., Denny W.A. Tyrosine Kinase Inhibitors. 12. Synthesis and Structure Activity Relationships for 6-Substituted 4-(Phenylamino)Pyrimido[5,4-d]Pyrimidines Designed as Inhibitors of the Epidermal Growth Factor Receptor. J. Med. Chem. 1997; 40: 1820–1826
   PubMed Web of Science ®Google Scholar
• Voldborg B.R., Damstrup L., Spang-Thornsen M., Poulson H.S. Epidermal Growth Factor Receptor and EGFR Mutations, Function and Possible Role in Clinical Trials. Ann. Oncol. 1997; 8: 1197–1206
   PubMed Web of Science ®Google Scholar
• Carpenter G., Cohen S. Epidermal Growth Factor. J. Biol. Chem. 1990; 265: 7709–7712
   PubMed Web of Science ®Google Scholar
• Margolis B., Bellot F., Honegger A.M., Ulrich A. Tyrosine Kinase Activity Is Essential for the Association of Phospholipase C-γ with Epidermal Growth Factor Receptor. Mol. Cell Biol. 1990; 10: 435–441
   PubMed Web of Science ®Google Scholar
• Yaish P., Gazit A., Gilon C., Levitzki A. Blocking of EGF-Dependent Cell Proliferation by EGF Receptor Kinase Inhibitors. Science 1988; 242: 933–935
   PubMed Web of Science ®Google Scholar
• Gazit A., Yaish P., Gilon C., Levitzki A. Tyrphostins 1: Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors. J. Med. Chem. 1989; 32: 2344–2352
   PubMed Web of Science ®Google Scholar
• Gazit A., Osherov N., Posner I., Yaish P., Poradosu E., Gilon C., Levitzki A. Tyrphostins 2: Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF receptor and erbB2/neu Tyrosine Kinases. J. Med. Chem. 1991; 34: 1896–1907
   PubMed Web of Science ®Google Scholar
• Gazit A., Osherov N., Posner I., Bar-Sinai A., Gilon C., Livitzki N. Tyrphostins 3: Structure–Activity Relationship Studies of α-Substituted Benzylidenemalononitrile 5-s-Aryltyrphostins. J. Med. Chem. 1993; 36: 3556–3564
   PubMed Web of Science ®Google Scholar
• Yoneda T., Lyall R.M., Alsina M.M., Persons P.E., Spada A.P., Levitzki A., Zilberstein A., Mundy G.R. The Antiproliferative Effects of Tyrosine Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma In Vitro and in Nude Mice. Cancer Res. 1991; 51: 4430–4435
   PubMed Web of Science ®Google Scholar
• Trinks U., Buchdunger E., Furet P., Kump W., Mett H., Meyer T., Muller M., Regenass U., Rihs G., Lydon N. Dianilinophthalimides: Potent and Selective ATP Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1994; 37: 1015–1027
   PubMed Web of Science ®Google Scholar
• Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase. Science 1994; 265: 1093–1095
   PubMed Web of Science ®Google Scholar
• Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal Growth Factor Receptor Tyrosine Kinase Investigation of Catalytic Mechanism, Structure Based Searching and Discovery of a Potent Inhibitor. Biochem. Pharmacol. 1994; 48: 659–666
   PubMed Web of Science ®Google Scholar
• Woodburn J.R., Barker A.J., Gibson K.H., Ashton S.E., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. ZD1839, an Epidermal Growth Factor Tyrosine Kinase Inhibitor Selected for Clinical Development. Proc. Annu. Meet. Am. Assoc. Cancer Res. 1997; 38: 633
   Google Scholar
• Ferry D., Hammond L., Ranson M., Kris M., Miller V, Murray P., Tullo A., Feyereislova A., Averbuch S., Rowinsky E. Intermittent Oral ZD1839 (Iressa), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), Shows Evidence of Good Tolerability and Activity: Final Results from a Phase I Study. Proc. Am. Soc. Clin. Oncol. 2000; 19: 3a
   Google Scholar
• Nakagawa K., Yamamoto N., Kudoh S., Negoro S., Takeda K., Tamura T., Fukuoka M. A Phase I Intermittent Dose-Escalation Trial of ZD1839 (Iressa) in Japanese Patients with Solid Malignant Tumors. Proc. Am. Soc. Clin. Oncol. 2000; 19: 183a
   Google Scholar
• Baselga J., Herbst R., LoRusso P., Rischin D., Ranson M., Plummer R., Raymond E., Maddox A., Kaye S.B., Kieback D.G., Harris A., Ochs J. Continuous Administration of ZD1839 (Iressa), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability. Proc. Am. Soc. Clin. Oncol. 2000; 19: 177a
   Google Scholar
• Sui L.L., Hidalgo M., Nemunaitis J., Rizzo J., Moczygemba J., Eckhardt S.G., Tolcher A., Smith L., Hammond L., Blackburn A., Tensfeldt T., Silberman S., Von Hoff D.D., Rowinsky E.K. Dose and Schedule Duration Escalation of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor CP-358,774: a Phase I and Pharmacokinetic (PK) Study. Proc. Am. Soc. Clin. Oncol. 1999; 18: 388a
   Google Scholar
• Karp D.D., Ferrante K.J., Tensfeldt T.G., Thurer R.L., LoCicero J., Huberman M.S., Wirth F., Hellman R., Poulin P., Silberman S.L., Redifer P., Allen L.F., Posner M., Schnipper L.E. A Phase I Dose Escalation Study of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) Inhibitor CP-358,774 in Patients with Advanced Solid Tumors. Lung Cancer 2000; 29(Suppl. 1)65
   Google Scholar
• Vincent P.W., Bridges A.J., Dykes D.J., Fry D.W., Leopold W.R., Patmore S.J., Roberts B.J., Rose S., Sherwood V., Zhou H., Elliot W.L. Anticancer Efficacy of the Irreversible EGFR Tyrosine Kinase Inhibitor PD 0169414 Against Human Tumor Xenografts. Cancer Chemother. Pharmacol. 2000; 45: 231–238
   PubMed Web of Science ®Google Scholar
• Medina L., Gomez L., Cerna C., Kraker A., Yochmowitz M., Weitman S. Investigation of the Effects of the Tyrosine Kinase Inhibitor CI-1033 (PD0183805) Against Human Tumor Specimens Taken Directly from Patients. Proc. Am. Assoc. Cancer Res. 2000; 41: 483
   Google Scholar
• Torrance C.J., Jackson P.E., Montgomery E., Kinzler K.W., Vogelstein B., Wissner A., Nunes M., Frost P., Discafani C.M. Combinatorial Chemoprevention of Intestinal Neoplasia. Nat. Med. 2000; 6: 1024–1028
   PubMed Web of Science ®Google Scholar
• Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., Gilliland D.G., Druker B.J. CGP57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing bcr–abl, tel–abl, and tel–pdgfr Fusion Proteins. Blood 1997; 90: 4947–4952
   PubMed Web of Science ®Google Scholar
• Beran M., Cao X., Estrov Z., Jeha S., Jin G., O'Brien S., Talpaz M., Arlinghaus R.B., Lydon N.B., Kantarjian H. Selective Inhibition of Cell Proliferation and bcr–abl Phosphorylation in Acute Lymphoblastic Leukemia Cells Expressing Mr 190,000 bcr–abl Protein by a Tyrosine Kinase Inhibitor (CGP57148). Clin. Cancer Res. 1998; 4: 1661–1672
   PubMed Web of Science ®Google Scholar
• Deininger M.W., Goldman J.M., Lydon N., Melo J.V. The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of bcr–abl Positive Cells. Blood 1997; 90: 3691–3698
   PubMed Web of Science ®Google Scholar
• Mandanas R.A., Leibowitz D.S., Gharehbaghi K., Tauchi T., Burgess G.S., Miyazawa K., Jayaram H.N., Boswell H.S. Role of p21 Ras in p210 bcr–abl Transformation of Murine Myeloid Cells. Blood 1993; 82: 1838–1847
   PubMed Web of Science ®Google Scholar
• Skorski T., Nieborowska-Skorska M., Szczylik C., Kanakaraj P., Perrotti D., Zon G., Gewirtz A, Prussia B., Calabretta B. c-raf-1 Serine/Threonine Kinase Is Required in bcr/abl-Dependent and Normal Hematopoiesis. Cancer Res. 1995; 55: 2275–2278
   PubMed Web of Science ®Google Scholar
• Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M.Z., Wen S.C., Zon G., Gewirtz A.M., Perussia B., Calabretta B. Phosphatidylinositol-3 Kinase Activity Is Regulated by bcr–abl and Is Required for the Growth of Philadelphia Chromosome Positive Cells. Blood 1995; 86: 726–736
   PubMed Web of Science ®Google Scholar
• Daley G.Q., Van Etten R.A., Baltimore D. Induction of Chronic Myelogenous Leukemia in Mice by the p210bcr/abl Gene of the Philadelphia Chromosome. Science 1990; 247: 824–830
   PubMed Web of Science ®Google Scholar
• LeCoutre P., Mologni L., Cleris L., Marchesi E., Buchdunger E., Giardini R., Formelli F., Gambacorti-Passerini C. In Vivo Eradication of Human bcr–abl Positive Leukemia Cells with an abl Kinase Inhibitor. J. Natl Cancer Inst. 1999; 91: 163–168
   PubMed Web of Science ®Google Scholar
• Druker B.J., Talpaz M., Resta D., Peng B., Buchdunger E., Ford J., Sawyers C.L. Clinical Efficacy and Safety of an abl Specific Tyrosine Kinase Inhibitor as Targeted Therapy for Chronic Myelogenous Leukemia. Blood 1999; 94: 368a
   PubMedGoogle Scholar
• Witters L., Kumar R., Mandal M., Bennett C.F., Miraglia L., Lipton A. Antisense Oligonucleotides to the Epidermal Growth Factor Receptor. Breast Cancer Res. Treat. 1999; 53: 41–50
   PubMed Web of Science ®Google Scholar
• Normanno N., Bianco C., Damiano V., de Angelis E., Selvam M.P., Grassi M., Magliulo G., Tortora G., Bianco A.R., Mendelsohn J., Salomon D.S., Ciardiello F. Growth Inhibition of Human Colon Carcinoma Cells by Combinations of Anti-Epidermal Growth Factor-Related Growth Factor Antisense Oligonucleotides. Clin. Cancer Res. 1996; 2: 601–609
   PubMed Web of Science ®Google Scholar
• Arteaga C.L., Hurd S.D., Dugger T.C., Winnier A.R., Robertson J.B. Epidermal Growth Factor Receptors in Human Breast Carcinoma Cells: a Potential Selective Target for Transforming Growth Factor α-Pseudomonas Exotoxin 40 Fusion Protein. Cancer Res. 1996; 54: 4703–4709
   Web of Science ®Google Scholar
• Lei W., Mayotte J.E., Levitt M.L. Enhancement of Chemosensitivity and Programmed Cell Death by Tyrosine Kinase Inhibitors Correlates with EGFR Expression in Non-Small Cell Lung Cancer Cells. Anticancer Res. 1998; 19: 221–228
   Web of Science ®Google Scholar
• Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., DePlacido S., Bianco A.R., Tortora G. Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD1839 (Iressa), an EGFR-Selective Tyrosine Kinase Inhibitor. Proc. Am. Assoc. Cancer Res. 2000; 41: 482
   Google Scholar
• Rowinsky E., Windle J.J., Von Hoff D.D. Ras Protein Farnesyltransferase: a Strategic Target for Anticancer Therapeutic Development. J. Clin. Oncol. 1999; 17: 3631–3652
   PubMed Web of Science ®Google Scholar
• Hancock J.F., Magee A.I., Childs J.E., Marshall C.J. All Ras Proteins Are Polyisoprenylated But Only Some Are Palmitoylated. Cell 1989; 57: 1167–1177
   PubMed Web of Science ®Google Scholar
• Hancock J.F., Paterson H., Marshall C.J. A Polybasic Domain or Palmitoylation Is Required for the Addition of the CAAX Motif to Localize p21 to the Plasma Membrane. Cell 1990; 63: 133–139
   PubMed Web of Science ®Google Scholar
• Jackson J.H., Cochrane C.G., Bourne J.R., Solski P.A., Buss J.E., Der C.J. Farnesyl Modification of Kirsten-Ras Exon 4B Protein Is Essential for Transformation. Proc. Natl Acad. Sci. USA 1990; 87: 3042–3046
   PubMed Web of Science ®Google Scholar
• Kato K., Cox A.D., Hisaka M.M., Graham S.M., Buss J.E., Der C.J. Isoprenoid Addition to Ras Protein Is the Critical Modification for Its Membrane Association and Transforming Activity. Proc. Natl Acad. Sci. USA 1992; 89: 6403–6407
   PubMed Web of Science ®Google Scholar
• Khosravi-Far R., Der C.J. The Ras Signal Transduction Pathway. Cancer Metastasis Rev. 1994; 13: 67–89
   PubMed Web of Science ®Google Scholar
• Prendergast G.C., Gibbs J.B. Pathways of Ras Function: Connections to the Actin Cytoskeleton. Adv. Cancer Res. 1993; 62: 19–64
   PubMed Web of Science ®Google Scholar
• Lange-Carter C.A., Johnson G.L. Ras Dependent Growth Factor Regulation of MEK Kinase in PC12 Cells. Science 1994; 265: 1458–1461
   PubMed Web of Science ®Google Scholar
• Tahey M., McCormick F. A Cytoplasmic Protein Stimulates Normal N-Ras p21 GTPase, But Does Not Affect Oncogenic Mutants. Science 1987; 238: 542–545
   PubMed Web of Science ®Google Scholar
• Buss J.E., Solski P.A., Schaeffer J.P., MacDonald M.J., Der C.J. Activation of Cellular Proto-Oncogene Product p21ras by Addition of a Myristylation Signal. Science 1989; 243: 1600–1603
   PubMed Web of Science ®Google Scholar
• Reiss Y., Goldstein J.L., Seabra M.C., Casey P.J., Brown M.S. Inhibition of Purified p21ras Farnesyl Protein Transferase by CysAAX Tetrapeptides. Cell 1990; 62: 81–88
   PubMed Web of Science ®Google Scholar
• Gelb M.H. Protein Prenylation, et cetera: Signal Transduction in Two Dimensions. Science 1997; 275: 1750–1751
   PubMed Web of Science ®Google Scholar
• End D., Skrzat S., Devine A., Angibaud P., Venet M., Sanz G., Bowden C. R115,777, a Novel Imidazole Farnesyl Protein Transferase Inhibitor: Biochemical and Cellular Effects in H-Ras and K-Ras Dominant Systems. Proc. Am. Assoc. Cancer Res. 1998; 39: 270
   Google Scholar
• Todd A.V., Applegate T.L., Feury C.J., Roberts N.J., Impey H.L., Devine A., Skrzat S., End D.W. Farnesyl Transferase Inhibitor (FTI): Effect on Ras Activation. Proc. Am. Assoc. Cancer Res. 1998; 39: 317
   Google Scholar
• Gibbs J.B., Oliff A. The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics. Annu. Rev. Pharmcol. Toxicol. 1997; 37: 143–166
   PubMed Web of Science ®Google Scholar
• Skrzat S., Angibaud P., Venet M., Sanz G., Bowden C., End D. R115,777, a Novel Imidazole Farnesyl Protein Transferase Inhibitor: Biochemical and Cellular Effects in H-Ras and K-Ras Dominant Systems. Proc. Am. Assoc. Cancer Res. 1998; 39: 317
   Google Scholar
• Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., Malkowski M., Ferrari E., Nielsen L, Prioli N., Dell J., Sinha D., Syed J., Korfmacher W.A., Nomeir A.A., Lin C.C., Wang L, Taveras A.G., Doll R.J., Njoroge F.G., Mallams A.K., Remiszewski S., Catino J.J., Girijavallabhan V.M., Bishop W.R. Antitumor Activity of SCH66356, an Orally Bioavailable Tricyclic Inhibitor of Farnesyl Protein Transferase, in Human Tumor Xenograft Models and Wap–Ras Transgenic Mice. Cancer Res. 1998; 58: 4947–4956
   PubMed Web of Science ®Google Scholar
• Britten C.D., Rowinsky E., Yao S.-L., Soignet S., Rosen N., Eckhardt S.G., Drengler R., Hammond L., Siu L.L., Smith L, McCreery H., Pezzulli S., Lee Y., Lobell R., Deutsch P., Von Hoff D., Spriggs D. The Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Cancers. Proc. Am. Soc. Clin. Oncol. 1999; 18: 155a
   Google Scholar
• Rubin E., Abbruzzese J.L., Morrison B.W., Mazina K., Lee Y., Zamek R., Berg D., Taebel K., Kher U., Deutsch P., Fuchs C. Phase I Trial of the Farnesyl Protein Transferase Inhibitor L-778,123 on a 14 or 28 Day Dosing Schedule. Proc. Am. Soc. Clin. Oncol. 2000; 19: 178a
   Google Scholar
• Bishop W.R., Bond R., Petrin J., Wang L., Patton R., Doll R., Njoroge G., Catino J., Schwartz J., Windsor W. Novel Tricyclic Inhibitors of Farnesyl Protein Transferase. J. Biol. Chem. 1995; 270: 30611–30618
   PubMed Web of Science ®Google Scholar
• Eskens F., Awada A., Verweij J., Culter D.L., Hanauske A., Piccart M. Phase I and Pharmacologic Study of Continuous Daily Oral SCH66336, a Novel Farnesyl Transferase Inhibitor, in Patients with Solid Tumors. Proc. Am. Soc. Clin. Oncol. 1999; 18: 156a
   Google Scholar
• Hurwitz H.I., Colvin O.M., Petros W.P., Williams R., Conway D., Adams D.J., Casey P.J., Calzetta A., Mastorides P., Statkevich P., Culter D. A Phase I and Pharmacokinetic Study of SCH66336, a Novel FTI Using a 2 Week on, 2 Week off Schedule. Proc. Am. Soc. Clin. Oncol. 1999; 18: 156a
   Google Scholar
• Adjei A.A., Erlichman C., Davis J.N., Cutler D.L., Sloan J.A., Marks R.S., Hanson L.J., Svingen P.A., Atherton P., Bishop W.R., Kirschmeier P., Kaufmann S.H. A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity. Cancer Res. 2000; 60: 1871–1877
   PubMed Web of Science ®Google Scholar
• James G.L., Goldstein J.J.L., Brown M.S., Rawson T.E., Somers T.C., McDowell R.S., Crowley C.W., Lucas B.K., Levinson A.D., Marsters J.C., Jr. Benzodiazepine Peptidomimetics: Potent Inhibitors of Ras Farnesylation in Animal Cells. Science 1993; 260: 1937–1942
   PubMed Web of Science ®Google Scholar
• Zujewski J., Horak I.D., Bol C.J.J.G., Woestenborghs R., End D., Chiao J., Belly R.T., Kohler D., Chow C., Noone M., Hakim F.T., Larkin G., Gress R.E., Nussenblatt R.B., Kremer A.B., Cowan K.H. Phase I Trial of Farnesyl-Transferase Inhibitor R115,777 in Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 192a
   Google Scholar
• Hudes G.R., Schol J., Baab J., Rogatko A., Bol C., Horak I., Langer C., Goldstein L.J., Szarka C., Meropol N.J., Weiner L. Phase I Clinical and Pharmacokinetic Trial of the Farnesyl Transferase Inhibitor R115,777 on a 21 Day Dosing Schedule. Proc. Am. Soc. Clin. Oncol. 1999; 18: 156a
   Google Scholar
• Schellens J.H.M., de Klerk G., Swart M., Palmer P.A., Bol C.J., van't Veer L.J., Tan S., de Gast G.C., Beijnen J.H., ten Bokkel Huinink W.W. Phase I and Pharmacologic Study with the Novel Farnesyltransferase Inhibitor R115,777. Proc. Am. Soc. Clin. Oncol. 2000; 19: 184a
   Google Scholar
• Lancet J., Rosenblatt J., Liesveld J.L., End D., Hovak I., Ange D., Rosell K., Petronio S., Smith A., Karp J. Use of Farnesyl Transferase Inhibitor R115,777 in Relapse and Refractory Acute Leukemias. Proc. Am. Soc. Clin. Oncol. 2000; 19: 3a
   Google Scholar
• Johnson S.R., Ellis P.A., Houston S., Hickish T., Howes A.J., Palmer P., Horak I. A Phase II Study of the Farnesyl Transferase Inhibitor R115,777 in Patients with Advanced Breast Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 83a
   Google Scholar
• Whyte D.B., Kirschmeier P., Hockenberry T.N., Nunez-Oliva I, James L., Catino J.J., Bishop W.R., Pai J.K. K- and N-Ras are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors. J. Biol. Chem. 1997; 272: 14459–14464
   PubMed Web of Science ®Google Scholar
• Rowell C.A., Kowalczyk J.J., Lewis M.D., Garcia A.M. Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras In Vivo. J. Biol. Chem. 1997; 272: 14093–14097
   PubMed Web of Science ®Google Scholar
• Cox A.D., Der C.J. Farnesyltransferase Inhibitors and Cancer Treatment: Targeting Simply Ras?. Biochim. Biophys. Acta 1997; 1333: F51–F71
   PubMed Web of Science ®Google Scholar
• James G.L., Goldstein J.L., Brown M.S. Resistance of K-RasBV12 Proteins to Farnesyltransferase Inhibitors in rat1 Cells. Proc. Natl Acad. Sci. USA 1996; 93: 4454–4458
   PubMed Web of Science ®Google Scholar
• Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K. Inhibition of Farnesyltransferase Induces Regression of Mammary and Salivary Carcinomas in Ras Transgenic Mice. Nat. Med. 1995; 1: 792–797
   PubMed Web of Science ®Google Scholar
• Prendergast G.C., Davide J.P., Lebowitz P.F., Wechsler-Reya R., Kohl N.E. Resistance of a Variant Ras-Transformed Cell Line to Phenotypic Reversion by Farnesyl Transferase Inhibitors. Cancer Res. 1996; 56: 2626–2632
   PubMed Web of Science ®Google Scholar
• Lerner E.C., Zhang T.T., Knowles D.B., Qian Y., Hamilton A.D., Sebti S.M. Inhibition of the Prenylation of k-Ras But Not h- or n-Ras Is Highly Resistant to Caax Peptidomimetics and Requires Both a Farnesyltransferase and a Geranylgeranyltransferase I Inhibitor in Human Tumor Cell Lines. Oncogene 1997; 15: 1283–1288
   PubMed Web of Science ®Google Scholar
• James G.L., Goldstein J.L., Brown M.S. Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetics In Vitro. J. Biol. Chem. 1995; 270: 6221–6226
   PubMed Web of Science ®Google Scholar
• Trueblood C.E., Ohya Y., Rine J. Genetic Evidence for In Vivo Cross Specificity of the Caax-Box Protein Prenyltransferase Farnesyltransferase and Geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol. Cell Biol. 1993; 13: 4260–4275
   PubMed Web of Science ®Google Scholar
• Sepp-Lorenzino L., Ma Z., Rands E., Kohl N.E., Gibbs J.B., Oliff A., Rosen N. A Peptidomimetic Inhibitor of Farnesyl Protein Transferase Blocks the Anchorage-Dependent and Independent Growth of Human Tumor Cell Lines. Cancer Res. 1995; 55: 5302–5309
   PubMed Web of Science ®Google Scholar
• Lebowitz P.F., Davide J.P., Prendergast G.C. Evidence that Farnesyl Transferase Inhibitors Suppress Ras Transformation by Interfering with Rho Activity. Mol. Cell Biol. 1995; 15: 6613–6622
   PubMed Web of Science ®Google Scholar
• Prendergast G.C., Davide J.P., deSolms S.J., Giuliani E.A., Graham S.L., Gibbs J.B., Oliff A., Kohl N.E. Farnesyltransferase Inhibition Causes Morphological Reversion of Ras-Transformed Cells by a Complex Mechanism That Involves Regulation of the Actin Cytoskeleton. Mol. Cell Biol. 1994; 14: 4193–4202
   PubMed Web of Science ®Google Scholar
• Prendergast G.C. Farnesyltransferase Inhibitors: Antineoplastic Mechanism and Clinical Prospects. Curr. Opin. Cell Biol. 2000; 12: 166–173
   PubMed Web of Science ®Google Scholar
• Adamson P., Marshall C.J., Hall A., Tilbrook P.A. Post-translational Modification of p21rho Proteins. J. Biol. Chem. 1992; 267: 20033–20038
   PubMed Web of Science ®Google Scholar
• Lebowitz P.F., Casey P., Prendergast G.C., Thissen J.A. Farnesyltransferase Inhibitors Alter the Prenylation and Growth Stimulating Function of Rho-b. J. Biol. Chem. 1997; 272: 15591–15594
   PubMed Web of Science ®Google Scholar
• Du W., Lebowitz P.F., Prendergast G.C. Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB. Mol. Cell Biol. 1999; 19: 1831–1840
   PubMed Web of Science ®Google Scholar
• Skrzat S.G., Gowden C.R., End D.W. Interaction of the Farnesyl Protein Transferase Inhibitor R115,777 with Cytotoxic Chemotherapeutics In Vitro and In Vivo. Proc. Am. Assoc. Cancer Res. 1999; 40: 523
   Google Scholar
• Shi B., Gurnani M., Yaremko B., Lee S., Chen J., Lipari P., Ferrari E., Malkowski M., Liu M., Gerald Hajian G., Nielsen L.L. Enhanced Efficacy of the Farnesyl Protein Transferase Inhibitor SCH66336 in Combination with Paclitaxel. Proc. Am. Assoc. Cancer Res. 1999; 40: 524
   Google Scholar
• Bernhard E.J., Kao G., Cox A.D., Sebti S.M., Hamilton A.D., Muschel R.J., McKenna W.G. The Farnesyl Transferase Inhibitor FTI-277 Radiosensitizes H-Ras Transformed Rat Embryo Fibroblasts. Cancer Res. 1996; 56: 1727–1730
   PubMed Web of Science ®Google Scholar
• Patnaik A., Eckhardt S., Itzbicka E., Hidalgo M., McCreery H., Mori M., Terada K., Tolcher A., Smith L., Britten C., Bowden C., Bol K., Ochon L., Davidson K., Hammond L., Schwartz G., Horak I., Gentner L., Rowinsky E. A Phase I and Pharmacokinetic Study of the Farnesyltransferase Inhibitor R115,777 in Combination with Gemcitabine. Proc. Am. Soc. Clin. Oncol. 2000; 19: 2a
   Google Scholar
• Hurwitz H.I., Amado R., Prager D., Hecht J.R., Cohen D.P., Conway D., Kadib L., Mayers A., Calzetta A., Statkevich P., Cutler D.L., Rosen L.S. Phase I Pharmacokinetic Trial of the Farnesyl Transferase Inhibitor SCH6636 Plus Gemcitabine in Advanced Cancers. Proc. Am. Soc. Clin. Oncol. 2000; 19: 185a
   Google Scholar
• Gordon M.S., Sandler A.B., Holmlund J.T., Dorr A., Battiato L., Fife K., Geary R., Kwoh T.J., Sledge G.W., Jr. A Phase I Trial of ISIS 2503, an Antisense Inhibitor of h-Ras Administered by a 24 Hour Weekly Infusion to Patients with Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 157a
   Google Scholar
• Dorr A., Bruce J., Monia B., Johnston J., Geary R., Kwoh T.J., Holmlund J., Nemunaitis J. Phase I and Pharmacokinetic Trial of ISIS 2503, a 20-Mer Antisense Oligonucleotide Against h-Ras by 14-Day Continuous Infusion in Patients with Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 1999; 18: 157a
   Google Scholar
• Stevenson J.P., Yao K.S., Gallagher M., Friedland D., Mitchell E.P., Cassella A., Monia B., Kwoh T.J., Yu R., Holmlund J., Dorr F.A., O'Dwyer P.J. Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP69846A). J. Clin. Oncol. 1999; 17: 2227–2236
   PubMed Web of Science ®Google Scholar
• Adjei A.A., Erlichman C., Sloan J.A., Hanson L.J., Reid J., Atherton P., Geary R., Holmlund J., Dorr A. A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-Ras in Combination with Gemcitabine in Patients with Advanced Cancer. Proc. Am. Soc. Clin. Oncol. 2000; 19: 186a
   Google Scholar
• Gelmon K.A., Eisenhauer E.A., Harris A.L., Ratain M.J., Workman P. Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development. J. Natl Cancer Inst. 1999; 91: 1281–1287
   PubMed Web of Science ®Google Scholar